Fresenius Kabi debuts generic Vimpat

Fresenius Kabi is introducing lacosamide injection, a generic equivalent to UCB’s Vimpat.

The medication is an approved treatment option for partial-onset seizures in patients aged 17 years old and older and is available in 200 mg per 20 ml single-dose vials.

“Fresenius Kabi is pleased to provide the clinicians and patients who rely on us with high quality and accessible choices for treating patients with certain seizures,” said John Ducker, president and CEO of Fresenius Kabi USA.

[Read more: Fresenius Kabi intros generic Tepadina]

Fresenius Kabi's generic Vimpat for intravenous use is indicated for the treatment of partial-onset seizures in patients aged 17 years old and older. 

The pediatric use information is approved for UCB’s Vimpat. Due to UCB’s marketing exclusivity rights, the Fresenius Kabi drug product is not labeled with that pediatric information.